Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors

NCT01804530 is registered in ClinicalTrials.gov with Plexxikon as lead sponsor.

NCT NCT01804530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01804530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors
Lead sponsor
Plexxikon
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2013
Completion date
January 24, 2018
Enrollment
59 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, tenosynovial giant cell tumor, tumors of any histology with activating trk (ntrk) point or ntrk fusion mutations